NASDAQ
SKIN
Last Price
US $0.86
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
The Beauty Health Company cash flow to debt ratio of 9.90% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial stability - Healthy cash flow growth.
The Beauty Health Company's free cash flow has increased 298.09% from $9.34M last year to $37.18M, signaling increasing performance
Financial risk - Healthy debt to equity ratio.
The Beauty Health Company's debt to equity ratio is 6.65, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial stability - Healthy debt to equity ratio development.
The Beauty Health Company's debt has decreased relative to shareholder equity from 10.97 last year to 6.65 today, signaling strengthened financials
Financial risk - Net debt/EBITDA.
The Beauty Health Company has a net debt to EBITDA ratio of 3.77x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk
Financial risk - ICR.
The Beauty Health Company's interest coverage ratio is -0.46, which means that the company struggles to meet interest obligations, signaling financial risk.
Financial stability - Profit margin growth.
The Beauty Health Company's profit margin has increased (-76.63%) in the last year from -8.70% to -2.03%, signaling increasing performance
Financial stability - Short term assets vs short term liabilities.
The Beauty Health Company's short-term assets of $309.50M exceed its short-term liabilities of $186.30M
Decreasing performance - ROA.
The Beauty Health Company's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
The Beauty Health Company's return on equity of -9.41%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
The Beauty Health Company's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
The Beauty Health Company had positive net income in only 1.00 out of 5 years, indicating unstable earnings
Increasing performance - Free cash flow.
The Beauty Health Company has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
The Beauty Health Company has a free cash flow yield of 33.24%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
The Beauty Health Company's yearly earnings has increased -67.29% since last year from $-29.10M to $-9.52M, signaling increasing performance
Decreasing performance - Healthy revenue growth.
The Beauty Health Company's yearly revenue has decreased -10.02% since last year from $334.29M to $300.80M, signaling decreasing performance
Decreasing performance - ROIC.
ROIC -2.49% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
The Beauty Health Company's 3-year revenue CAGR of -6.32% is negative, indicating declining revenue over the past 3 years
Increasing performance - Revenue consistency.
The Beauty Health Company had revenue growth in 3.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
The Beauty Health Company had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
The Beauty Health Company has insufficient data to evaluate this check.
Overvalued - Earnings yield.
The Beauty Health Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
The Beauty Health Company is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Undervalued - EV/EBITDA.
The Beauty Health Company has an EV/EBITDA ratio of 6.66x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
The Beauty Health Company has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
The Beauty Health Company has a price-to-book ratio of 2.00x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
The Beauty Health Company has a price-to-sales ratio of 0.37x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
-9.41%
Return on equity
ROIC: -2.49%
Valuation History
-16.4X
Price to Earnings
EV/EBITDA: 6.4X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $0.86
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.